Predict your next investment

Corporation
SOFTWARE (NON-INTERNET/MOBILE) | Business Intelligence, Analytics & Performance Mgmt Software
bioinfogate.com

See what CB Insights has to offer

Investments

1

Partners & Customers

2

About Bioinfogate

Bioinfogate is a provider of analytics solutions in the life sciences and producer of the OFF-X™ portal.On August 4th, 2021, Bioinfogate was acquired by Clarivate Analytics. Terms of the transaction were not disclosed.

Bioinfogate Headquarter Location

Via Augusta 59 Office 707

Barcelona, 08006,

Spain

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Bioinfogate News

Clarivate : Bioinfogate's OFF-X Reaches One Million Safety Alerts

Oct 14, 2021

10/14/2021 | 05:52pm EDT Message : *Required fields OFF-X has become the largest translational safety and toxicity intelligence portal for drugs and targets of pharmacological interest. Barcelona Launched in 2017, OFF-X has now reached 1,000,000 safety alerts corresponding to over 15,000 targets of pharmacological interest and more than 21,000 drugs and biologics. This represents the largest collection of data correlating toxicity and safety findings surrounding targets of pharmacological interest and their associated drugs, from early discovery up to pharmacovigilance. Unexpected safety issues still constitute one of the major challenges in drug R&D and clinical practice. It is therefore essential to rapidly identify these issues and react accordingly to minimize risks in pharmaceutical programs. To help in this endeavor, Bioinfogate has developed OFF-X, the translational safety intelligence portal, which provides integrated preclinical toxicity and clinical adverse event intelligence for drugs and targets in all phases of R&D, including first-in-class and emerging targets. The database is updated daily with information deriving from biomedical literature, congresses and scientific conferences, company communications, major clinical trial registries, pharmacovigilance data and regulatory agencies, and includes data from the last 50 years. These continued efforts have been paralleled with the incorporation of analytics to navigate and take full advantage of the OFF-X dataset. In that regard, recent enhancements in the OFF-X portal include the OFF-X Translatability Dashboard (supports understanding of how toxicity events derived from experimental assays and animal models translate to the clinic), the Secondary Pharmacology Section (an integrated view outlining relevant secondary pharmacology insights commonly used to delineate the safety profile of investigational drugs), updates to the OFF-X Chemistry Dashboard (assessment of potential compound- vs target-related liabilities), the Drug Combination Area (supports the discovery of potential synergistic adverse effects observed only in combination therapies), and the Adverse Event / SMQ view (allows users to navigate adverse events classified following Standardized MedDRA Queries). On reaching this milestone Dr Josep Prous, Jr, Executive Director at Bioinfogate commented: "We are very pleased that OFF-X has reached this milestone driven by the translational research needs for all those involved in finding better and safer drugs. Our team of analysts - comprised of specialists in multiple biomedical research disciplines - has made an outstanding contribution in reaching this milestone. We look forward to further developing the platform to help optimize pharmaceutical R&D and minimize patient risks in clinical trials and beyond". By enabling translational research, OFF-X allows safety liabilities to be monitored and anticipated across all phases of drug R&D and postmarketing. OFF-X is used across a wide range of departments in pharmaceutical research organizations, public health institutions and regulatory agencies. About OFF-X® Launched in 2016, OFF-X® is used across pharma and biotech organizations, in leading research centers and by regulatory bodies around the world, addressing the need for new approaches to enhance safety assessments that can reduce patient burden and avoid costly failures. The Bioinfogate OFF-X® portal provides integrated target discovery, non-clinical and clinical adverse event intelligence and pharmacovigilance insights for drugs and targets in all phases of drug R&D and post-marketing. By delivering critical integrated target discovery, preclinical toxicity, clinical adverse event intelligence and pharmacovigilance insights coupled to advanced analytics, Bioinfogate OFF-X, allows safety liabilities to be monitored and anticipated across all phases of drug R&D and post-marketing. OFF-X is updated daily and more than 4,000 expertly curated alerts are added to the portal each week. As of March 2021, the portal covers a range of over 15,000 targets and 21,500 drugs & biologics, and is populated with more than 1.1 million expertly curated safety alerts associated to over 10,000 adverse effects. OFF-X® is used across pharma and biotech organizations, in leading research centers and regulatory bodies. For more information visit targetsafety.info . About Clarivate Clarivate™ is a global leader in providing solutions to accelerate the lifecycle of innovation. Our bold mission is to help customers solve some of the world's most complex problems by providing actionable information and insights that reduce the time from new ideas to life-changing inventions in the areas of science and intellectual property. We help customers discover, protect and commercialize their inventions using our trusted subscription and technology-based solutions coupled with deep domain expertise. For more information, please visit clarivate.com. Investor Relations Contact investor.relations@clarivate.com

Bioinfogate Investments

1 Investments

Bioinfogate has made 1 investments. Their latest investment was in QUIBIM as part of their Seed VC on December 12, 2016.

CBI Logo

Bioinfogate Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

12/28/2016

Seed VC

QUIBIM

$0.57M

Yes

1

Date

12/28/2016

Round

Seed VC

Company

QUIBIM

Amount

$0.57M

New?

Yes

Co-Investors

Sources

1

Bioinfogate Partners & Customers

2 Partners and customers

Bioinfogate has 2 strategic partners and customers. Bioinfogate recently partnered with INTAGE Healthcare on October 10, 2020.

Date

Type

Business Partner

Country

News Snippet

Sources

10/15/2020

Vendor

INTAGE Healthcare

Japan

NEW COLLABORATION BETWEEN BIOINFOGATE AND INTAGE HEALTHCARE TO DELIVER JAPANESE PHARMACOVIGILANCE INSIGHTS IN OFF-X – Bioinfogate

Bioinfogate , a leading healthcare data science organization , today announced it has entered into a global agreement with INTAGE Healthcare to integrate Japanese pharmacovigilance insights from the JADER database .

1

2/28/2019

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

10/15/2020

2/28/2019

Type

Vendor

Partner

Business Partner

INTAGE Healthcare

Country

Japan

Subscribe to see more

News Snippet

NEW COLLABORATION BETWEEN BIOINFOGATE AND INTAGE HEALTHCARE TO DELIVER JAPANESE PHARMACOVIGILANCE INSIGHTS IN OFF-X – Bioinfogate

Bioinfogate , a leading healthcare data science organization , today announced it has entered into a global agreement with INTAGE Healthcare to integrate Japanese pharmacovigilance insights from the JADER database .

Subscribe to see more

Subscribe to see more

Sources

1

10

Bioinfogate Team

1 Team Member

Bioinfogate has 1 team member, including undefined undefined, undefined.

Name

Work History

Title

Status

Josep Prous

Founder

Current

Name

Josep Prous

Work History

Title

Founder

Status

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.